NCT05495035 2023-03-02
Study for Safety and Efficacy of Olverembatinib Combined With APG-2575 in Children With Relapsed/Refractory Ph + ALL
Institute of Hematology & Blood Diseases Hospital, China
Phase 1 Unknown
Institute of Hematology & Blood Diseases Hospital, China
Institute of Hematology & Blood Diseases Hospital, China
NSABP Foundation Inc
Keymed Biosciences Co.Ltd
National University of Ireland, Galway, Ireland
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)